# Clinical trials recruiting in South Korea: 2,164 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,164 trials recruiting or not yet recruiting with a site in South Korea, as read on November 19, 2026.

## The full list

Clinical trials recruiting in South Korea: 2,164 rows for $101.64, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 46 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/south-korea

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,164
- Recruiting or not yet: 2,164
- Read on: November 19, 2026

## Trials

The 25 newest of 2,164, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945288 | Safety and Feasibility of an Integrated Fabric-Type Orthosis for Gait and Balance Improvement in Geriatric Patients | Seoul National University Hospital | Not applicable | Recruiting | Sarcopenia, Older Adults (65 Years and Older), Gait Analysis, Balance, Orthotic Device | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945288) |
| November 18, 2026 | NCT07945106 | Development of an ASRS-Based Photoguide for a Clinical Trial of TRTP-101 in Adults With Atrophic Scars | CellinCells | Observational | Not yet recruiting | Atrophic Scar | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945106) |
| November 18, 2026 | NCT07944066 | SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis | Samsung Medical Center | Phase 4 | Recruiting | Aortic Valve Stenosis | 1,182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944066) |
| November 17, 2026 | NCT07943390 | A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza | Boryung Biopharma Co., Ltd. | Phase 3 | Recruiting | Influenza | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943390) |
| November 17, 2026 | NCT07942545 | Duration of Antibiotic Therapy Evaluation Study in Acute Cholangitis (DATES-AC): An Open-Label, Multicenter, Randomized Non-Inferiority... | Seoul National University Hospital | Not applicable | Not yet recruiting | Cholangitis Acute | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942545) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 17, 2026 | NCT07940933 | Niacin and Selenium Combination Therapy in Patients With Septic Shock | Seoul National University Hospital | Phase 2 | Not yet recruiting | Septic Shock | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940933) |
| November 16, 2026 | NCT07940296 | Safety and Efficacy of BioSeal as a Surgical Adhesive in Cardiovascular Surgery | DALIM TISSEN Co., Ltd. | Not applicable | Recruiting | Cardiovascular Surgery, Vascular Anastomosis Surgery | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940296) |
| November 16, 2026 | NCT07939087 | A Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Not yet recruiting | Healty Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939087) |
| November 16, 2026 | NCT07938281 | Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial) | Korea University Anam Hospital | Not applicable | Not yet recruiting | AF - Atrial Fibrillation | 1,006 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938281) |
| November 16, 2026 | NCT07937540 | Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure | Keimyung University Dongsan Medical Center | Not applicable | Recruiting | Heart Failure Patients, Heart Failure | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937540) |
| November 13, 2026 | NCT07936110 | How Different Breathing Methods Affect Brain Activity in Young Adults With Chronic Ankle Instability | Gwangju Health University | Not applicable | Recruiting | Chronic Ankle Instability, CAI, Young Adult | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936110) |
| November 13, 2026 | NCT07935200 | Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults | Korea United Pharm. Inc. | Phase 1 | Not yet recruiting | Bioequivalence, Pharmacokinetics | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935200) |
| November 12, 2026 | NCT07934290 | Hybrid Parasternal Intercostal Plane Block Versus No Block for Postoperative Analgesia After Cardiac Surgery Via Median Sternotomy | Sponsor not shown (see the record) | Not applicable | Not yet recruiting | Valve Disease, Heart, Coronary Artery Disease, Aorta Disease | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934290) |
| November 12, 2026 | NCT07933055 | Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan... | Txinno Bioscience Inc. | Phase 1/2 | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933055) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| November 12, 2026 | NCT07930507 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in... | AstraZeneca | Phase 3 | Not yet recruiting | Hypercholesterolemia | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930507) |
| November 12, 2026 | NCT07930260 | Efficacy and Safety of Kabalin Cap.(Pregabalin) in Patients With Neuropathic Pain | HK inno.N Corporation | Observational | Recruiting | Peripheral or Central Neuropathic Pain | 5,217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930260) |
| November 12, 2026 | NCT07930247 | Blood Pressure Control and Safety of Ex-one or Ex-one Plus in Essential Hypertension | HK inno.N Corporation | Observational | Recruiting | Essential Hypertension | 7,525 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930247) |
| November 10, 2026 | NCT07930169 | Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease Patients. | HK inno.N Corporation | Observational | Recruiting | Chronic Kidney Disease | 3,125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930169) |
| November 9, 2026 | NCT07926334 | A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926334) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 9, 2026 | NCT07926217 | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Hematologic Malignancy, Influenza | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926217) |
| November 9, 2026 | NCT07924345 | Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia Patients | HK inno.N Corporation | Observational | Recruiting | Dyslipidemia | 6,713 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924345) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Seoul National University Hospital | Seoul | 530 |
| Samsung Medical Center | Seoul | 512 |
| Asan Medical Center | Seoul | 405 |
| Seoul National University Bundang Hospital | Seongnam | 277 |
| Severance Hospital, Yonsei University Health System | Seoul | 166 |
| Severance Hospital | Seoul | 143 |
| Korea University Anam Hospital | Seoul | 139 |
| National Cancer Center | Goyang-si | 126 |
| Korea University Guro Hospital | Seoul | 119 |
| Pusan National University Hospital | Busan | 88 |
| Gachon University Gil Medical Center | Namdong-gu | 82 |
| Pusan National University Yangsan Hospital | Yangsan | 79 |
| Ajou University Hospital | Suwon | 79 |
| Chungbuk National University Hospital | Cheongju-si | 74 |
| Chonnam National University Hospital | Gwangju | 71 |
| Chonnam National University Hwasun Hospital | Hwasun | 69 |
| Severance Hospital Yonsei University Health System | Seoul | 66 |
| Kyungpook National University Chilgok Hospital | Deagu | 63 |
| Chungnam National University Hospital | Daejoen | 60 |
| Keimyung University Dongsan Hospital | Daegu | 58 |
| Inha University Hospital | Incheon | 52 |
| Ulsan University Hospital | Ulsan | 52 |
| Kyungpook National University Hospital | Daegu | 49 |
| Gangnam Severance Hospital | Seoul | 49 |
| Korea University Ansan Hospital | Ansan-si | 48 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 193 |
| Phase 1/2 | 180 |
| Phase 2 | 251 |
| Phase 2/3 | 44 |
| Phase 3 | 481 |
| Phase 4 | 123 |
| Not applicable | 449 |
| Observational | 443 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 103 |
| Breast Neoplasms | 95 |
| Coronary Artery Disease | 65 |
| Neoplasms | 64 |
| Stomach Neoplasms | 61 |
| Neoplasm Metastasis | 54 |
| Diabetes Mellitus, Type 2 | 53 |
| Ovarian Neoplasms | 48 |
| Atrial Fibrillation | 47 |
| Lung Neoplasms | 44 |
| Colorectal Neoplasms | 42 |
| Carcinoma, Hepatocellular | 41 |
| Heart Failure | 38 |
| Prostatic Neoplasms | 37 |
| Recurrence | 34 |
| Endometrial Neoplasms | 32 |
| Multiple Myeloma | 31 |
| Pancreatic Neoplasms | 31 |
| Crohn Disease | 27 |
| Stroke | 26 |
| Alzheimer Disease | 26 |
| Obesity | 26 |
| Hypertension | 24 |
| Cardiovascular Diseases | 24 |
| Squamous Cell Carcinoma of Head and Neck | 24 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Seoul National University Hospital | 161 |
| Yonsei University | 152 |
| Samsung Medical Center | 120 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 96 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 68 |
| Asan Medical Center | 53 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 41 |
| Seoul National University Bundang Hospital | 41 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 40 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 35 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 31 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 31 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 31 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 30 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 25 |
| Korea University Anam Hospital | 23 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 22 |
| [Addpharma Inc.](https://specstream.ai/data/clinical-trials/company/addpharma-inc) | 21 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 21 |
| National Cancer Center, Korea | 19 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 18 |
| Pusan National University Yangsan Hospital | 17 |
| [Daewoong Pharmaceutical Co. LTD.](https://specstream.ai/data/clinical-trials/company/daewoong-pharmaceutical-co-ltd) | 17 |
| Gangnam Severance Hospital | 17 |
| [Boryung Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/boryung-pharmaceutical-co-ltd) | 17 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
- [Georgian restaurants in the United States](https://specstream.ai/data/businesses/georgian-restaurants/united-states)
- [Walk-in clinics in the United States](https://specstream.ai/data/businesses/walk-in-clinics/united-states)
